| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
Kinase selectivity assays | Selectivity of UNC 0642 against a panel of 50 kinases was conducted using a standard off-chip mobility shift assay technology. |
Cell lines | PANC-1 and MDA-MB-231 cells |
Preparation method | The solubility of this compound in DMSO is >18.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months. |
Reacting condition | 0, 0.5 or 1 μM; 2 weeks |
Applications | UNC 0642 concentration-dependently reduced clonogenicity in PANC-1 cells but it showed no effect on clonogenicity in MDA-MB-231 cells. Besides, UNC 0642 potently reduced cellular levels of H3K9me2 with low cell toxicity, which resulted in a good separation of functional potency and cell toxicity with a tox/function ratio of 88 in PANC-1 cells. |
Animal models | Male Swiss Albino mice |
Dosage form | 5 mg/kg; i.p. |
Applications | A single intraperitoneal injection of 5 mg/kg UNC 0642 resulted in a plasma Cmax of 947 ng/mL and an AUC of 1265 h·ng/mL. However, UNC 0642 only displayed modest brain penetration, with a brain/plasma ratio of 0.33, which suggested that UNC 0642 might not be suitable for exploration of the role of G9a/GLP in the CNS. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | UNC0642 is a potent and selective G9a/GLP inhibitor, with an IC50 of less than 2.5 nM. UNC0642 displays high in vitro and cellular potency, low cell toxicity, and excellent selectivity. UNC0642 is competitive with the peptide substrate and non-competitive with the cofactor SAM. The Ki of UNC0642 is determined to be 3.7±1 nM. UNC0642 displays high in vitro potency for GLP (IC50< 2.5 nM), similar to G9a. UNC0642 is more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. UNC0642 exhibits high potency at reducing the H3K9me2 mark, low cell toxicity, and good separation of functional potency and cell toxicity in a number of cell lines. It reduces clonogenicity in PANC-1 cells, a pancreatic carcinoma cell line[1]. A single intraperitoneal (IP) injection (5 mg/kg) of UNC0642results in a plasma Cmax (maximum concentration) of 947 ng/mL and an AUC (area under the curve) of 1265 hr*ng/mL[1]. References: |
m.cnreagent.com